Evidence map›Paper›PMID 38617451›Full record

SynthesisWorld journal of gastroenterology2024

Effects of neoadjuvant chemotherapy

Armand Csontos, Alíz Fazekas, Lajos Szakó, Nelli Farkas, Csenge Papp, Szilárd Ferenczi, Szabolcs Bellyei, Péter Hegyi, András Papp

Open access · hybridAbstract readSystematic ReviewMeta-AnalysisComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Armand CsontosDepartment of Surgery, University of Pécs, Medical School, Clinical Center, Pécs H-7624, Baranya, Hungary. csontos.armand@gmail.com.
Alíz FazekasInstitute of Bioanalysis, University of Pécs, Medical School, Pécs H-7624, Baranya, Hungary.
Lajos SzakóDepartment of Emergency Medicine, Clinical Center, University of Pécs, Medical School, Pécs 7624, Baranya, Hungary.
Nelli FarkasInstitute of Bioanalysis, University of Pécs, Medical School, Pécs H-7624, Baranya, Hungary.
Csenge PappDepartment of Surgery, University of Pécs, Medical School, Clinical Center, Pécs H-7624, Baranya, Hungary.
Szilárd FerencziDepartment of Surgery, University of Pécs, Medical School, Clinical Center, Pécs H-7624, Baranya, Hungary.
Szabolcs BellyeiDepartment of Oncotherapy, University of Pécs, Medical School, Clinical Center, Pécs H-7624, Baranya, Hungary.
Péter HegyiInstitute for Translational Medicine, University of Pécs, Medical School, Pécs H-7624, Baranya, Hungary.
András PappDepartment of Surgery, University of Pécs, Medical School, Clinical Center, Pécs H-7624, Baranya, Hungary.
Semmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant therapy is an essential modality for reducing the clinical stage of esophageal cancer; however, the superiority of neoadjuvant chemotherapy (nCT) or neoadjuvant chemoradiotherapy (nCRT) is unclear. Therefore, a discussion of these two modalities is necessary.

aimTo investigate the benefits and complications of neoadjuvant modalities.

methodsTo address this concern, predefined criteria were established using the PICO protocol. Two independent authors performed comprehensive searches using predetermined keywords. Statistical analyses were performed to identify significant differences between groups. Potential publication bias was visualized using funnel plots. The quality of the data was evaluated using the Risk of Bias Tool 2 (RoB2) and the GRADE approach.

resultsTen articles, including 1928 patients, were included for the analysis. Significant difference was detected in pathological complete response (pCR) [

conclusionAlthough nCRT may have a higher pCR rate, it does not translate to greater long-term survival. Moreover, nCRT is associated with higher 30-d mortality, although the specific cause for postoperative complications could not be identified. In the case of nCT, toxic side effects are suspected, which can reduce the quality of life. Given the quality of available studies, further randomized trials are required.

Indexed as

AdenocarcinomaEsophageal NeoplasmsNeoadjuvant TherapyChemoradiotherapyChemoradiotherapy, AdjuvantChemotherapy, AdjuvantEsophagectomyHumansNeoplasm StagingQuality of LifeTreatment OutcomeAdenocarcinomaChemoradiotherapyChemotherapyEsophageal cancerNeoadjuvant

Identifiers

PMID38617451
PMCPMC11008422
OpenAlexW4393052597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.